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Abstract 
Gastrointestinal (GI) malignancies (esophageal, gastric, pancreatic, intra- and extra-biliary ductal, 
hepatocellular, and colorectal cancers) are an important cause of cancer incidence and mortality 
in the US and globally. GI cancers account for 15.4% and 23.8% of incident cancers and cancer- 
related deaths respectively in the US alone. Although earlier diagnosis and treatment advances 
have improved outcomes for some GI malignancies, the need for improved therapies in all disease 
phases (adjuvant, neoadjuvant and advanced) is paramount. Utilization of monoclonal antibodies 
targeting against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor 
(EGFR) has shown the success in selected colorectal carcinoma patients. More investigations of 
immunotherapy are on going in the treatment of GI malignances with different mechanisms and 
methods. In this article, we review data for established and evolving immunotherapy-related 
treatment options in GI malignancies. 
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1. Introduction 
Gastrointestinal (GI) malignancies refer to malignant neoplasms of the GI tract and accessory organs of diges- 
tion system: esophagus, stomach, liver and biliary system, pancreas, small intestine, colon and rectum, appendix 
and anus. Overall, GI malignancies account for more incident cases and deaths than any other organ system. 
However, these cancers are highly disparate: involving tumors of various histological types (e.g. adenocarcino- 
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ma vs. squamous carcinoma and others) and subtypes with vastly different incidences, lifetime risks and out- 
comes as outlined in Table 1. 
The primary intently curative treatment option for most GI malignancies is still surgical resection though 
combined modality therapy (concurrent chemotherapy and radiotherapy) has equivalent outcomes in anal cancer. 
Adjuvant and/or neoadjuvant chemotherapy or chemoradiotherapy has been shown to improve overall survival 
in select populations. However, given the absence of a proven screening modality in malignancies other than 
colonoscopy in colorectal cancer, most patients with cancers from GI system are diagnosed at an advanced stage. 
Effective screening modalities for cancers and discovering active chemotherapeutic, biologic agents in advanced 
disease are both areas of active investigational efforts in GI malignancies. 
Unlike melanoma and renal cell cancer in which immunotherapeutic options were a focus of early efforts, 
similar approaches in GI malignancies have only recently been exploited likely secondary to early successes 
with cytotoxic chemotherapy. However, observations support exploring immunotherapeutic modalities in GI 
malignancies: tumor associated antigens (TAA) associated with tumor-specific immune responses in esophageal 
(MAGE-A3/4 and NYESO-1), gastric (Her-2/neu), pancreatic (MUC1 and mesothelin), hepatocellular (AFP, 
GPC3, NY-ESO-1, SSX-2, MAGE-A and TERT) and colorectal (CEA) malignancies [1]-[12]; tumor-specific 
cytotoxic T-cells higher levels of which correlate with improved prognosis [13] [14]; and T-cell inhibitory fac-
tors [CD4+ Foxp3+ regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs)] higher levels of 
which correlate with poorer prognosis [15] [16]. In this article, we broadly delineate the various immunothera-
peutic options that have been or are explored in GI malignancies. 
2. Monoclonal Antibody Mediated Targeted Therapy 
2.1. EGFR Inhibition: Cetuximab (Erbitux®) and Panitumumab (Vectibix®) 
Epidermal growth factor receptor (EGFR) mediated signaling plays important roles in colorectal cancer (CRC) 
initiation and progression making EGFR inhibition an attractive target. There have been extensive studies in 
CRC regarding the efficacy, appropriate subpopulation and toxicity. However, limited studies have been pur- 
sued in esophageal, gastric, pancreatico-biliary and/or hepatocellular carcinomas. 
EGFR engages several downstream signaling cascades including PI3K (PI3K/AKT/mTOR) and MAP kinase 
(RAS/RAF/MEK/ERK) pathways which mediate cell differentiation, proliferation, and survival. RAS is a mem- 
brane bound protein which exchanges bound GDP for GTP and has intrinsic GTPase activity which ensures self- 
inactivation by GTP hydrolysis. RAS couples growth factor receptors to intracellular signaling pathways by ac- 
tivating downstream targets such as RAF, ERK1, ERK2 and PI3K that promote cell proliferation [17]. Three 
human RAS genes have been identified: HRAS, KRAS, and NRAS. Oncogenic KRAS typically contain single 
amino acid substitutions (most frequently, in codons 12/13/61) that produce KRAS proteins with strongly re- 
duced intrinsic GTPase activity resulting in constitutively activated GTP-bound state. Activating KRAS muta- 
tions are instrumental in the growth and proliferation of a wide variety of tumor types including melanoma, lung, 
CRC, thyroid and pancreatic carcinomas with a prevalence ranking from 11% (melanoma) to 95% (pancreatic 
adenocarcinoma) [18]. Uniquely in CRC, the chronological sequence of mutations during the tumorigenic pro-  
 
Table 1. Incidence and survival in GI malignancies.                                                            
 Cases in 2013 (% of New Cancer Cases) 
Incidence of New Cases 
(per 100,000 population, 
2006-2010) 
Deaths in 2013 (% 
of Cancer Deaths) 
Death Incidence (per 
100,000 population, 
2006-2010) 
5-Year Survival 
(%, 2003-2009) 
Lifetime 
Risk 
Colo-Rectal Cancer 142,820 (8.6%) 45.0 50,830 (8.8%) 16.4 64.9% 4.8% 
Pancreatic 45,220 (2.7%) 12.2 38,460 (6.6%) 10.9 6.0% 1.5% 
Liver and Bile Duct 
(intra-hepatic) 30,640 (1.8%) 7.7 21,670 (3.7%) 5.6 16.1% 0.9% 
Esophageal 17,990 (1.1%) 4.4 15,210 (2.6%) 4.3 17.3% 0.5% 
Small Intestine 8810 (0.5%) 2.1 1170 (0.2%) 0.4 64.5% 0.2% 
Anal 7060 (0.4%) 1.7 880 (0.2%) 0.2 65.6% 0.2% 
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality—All COD, Aggregated with 
State, Total US (1969-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, 
accessed March 30, 2014. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). 
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cess determines the eventual phenotype [19]. 
Cetuximab (a mouse/human chimeric, IgG1) and panitumumab (a full human, IgG2) are anti-EGFR monoc- 
lonal antibodies (MoAb) that competitively inhibit ligand-receptor binding and GTP phosphorylating, effective- 
ly disrupting downstream signaling. Additionally, given IgG1 isotype, cetuximab may activate complement 
pathway and mediate antibody-dependent cellular cytotoxicity (ADCC). Early phase studies of EGFR inhibition 
in CRC yielded positive results and prompted phase III studies [20]-[40]. Given KRAS’ role in mediating EGFR 
signaling, it was postulated that gain of function mutations would result in constitutively activated KRAS and 
consequent loss of sensitivity to EGFR inhibition in colorectal carcinoma. Proof of concept was initially pro-
vided by retrospective analysis of the NCIC CTG/AGITG CO17 phase III trial. KRAS mutation status was de-
termined in 68.9% of the original cohort, and was fortuitously well-balanced in both arms. Authors reported 
KRAS mutant patients did not benefit from cetuximab, while KRAS wild type (WT) patients had significantly 
improved PFS/OS [20] [21]. This observation was buttressed by analyses of the CRYSTAL and OPUS studies 
[26]. Other published data supports a lower rate of response to EGFR inhibition in patients with BRAF/ 
NRAS/HRAS mutations or activating mutations of PIK3CA pathway [41]. The FDA and EMA recommend that 
EGFR inhibitors be utilized only in KRAS WT patients, and NCCN guideline recommends further that EGFR 
inhibitorsshould only be considered in mCRC patients with KRAS and NRAS WT [42]. 
Cetuximab was the first EGFR inhibitor to be approved by the Food and Drug Administration (FDA) and Eu- 
ropean Medicine Agency (EMA) both as a single agent in relapsed/refractory colorectal carcinomaand together 
with combination chemotherapy in the 1st line setting on the basis of several randomized phase III studies. Sim- 
ilar results have been observed with panitumumab subsequently. These results are discussed below and depicted 
in Table 2. 
Since agents targeting both EGFR (cetuximab and panitumumab) and vascular endothelial growth factor 
(VEGF) (bevacizumab, ziv-aflibercept) have gained regulatory approval for KRAS/NRAS WT mCRCpatients, 
the sequence of application of either agent has been in debate. FIRE-3, a phase III randomizedstudy, compared 
FOLFIRI/cetuximab to FOLFIRI/bevacizumab in 592 KRAS WT patients as the first line therapy. Overall re- 
sponse rate (ORR) and median progression-free survival (mPFS) were similar in both arms, however, the me- 
dian overall-all survival (mOS) was significantly prolonged with the arm with cetuximabfirst compared to the 
arm with bevacizumabfirst (28.7 vs. 25.0 months respectively) despite greater treatment intensity in the bevaci- 
zumab arm [31]. Whether the improved mOS observed was related to cetuximab itself or post-progression ther- 
apy remains unclear as final results have yet to be published. CALGB/SWOG C80405 is a randomized phase III 
study of standard chemotherapy regimens (FOLFOX or FOLFIRI) in combination with either bevacizumab or 
cetuximab in KRAS WT patients as the first line therapy that completed accrual in 2012, the results of which 
may clarify this issue. 
Depending on whether patients were initially treated with a regimen with an oxaliplatin-backbone (FOLFOX/ 
XELOX) or an irinotecan-backbone (FOLFIRI/XELIRI), 2nd line therapy typically involves a switch between 
backbones. In KRAS/NRAS WT patients who did not received 1st line EGFR inhibition, adding either cetux- 
imab or panitumumab is advised. There is no data to guide decision making between cetuximab and panitumu- 
mab though the higher rate of cetuximab-related infusion reactions in certain geographical regions (in tandem 
with increased rates of atopy) is a practical consideration [43]. In KRAS/NRAS WT patients who received 1st 
line EGFR inhibition (either cetuximab or panitumumab), this is typically not continued at the time of progres- 
sion as cross-resistance is assumed given the similar mechanisms of action. Minimal data is available to address 
this issue: two clinical trials of panitumumab use in KRAS WT patients who progressed on cetuximab contain- 
ing regimens arrived at divergent conclusions [44] [45]. 
Somatic mutations in KRAS (<5% - 10%) and BRAF (2%) are unusual events in esophageal and gastric can- 
cers [46]. Non-randomized studies suggested added RFS/OS/RR benefit when cetuximab was added to conven- 
tional chemotherapy in advanced esophagogastric cancer. However, this was not borne out in 2 phase III rando- 
mized trials of gastric cancer (EXPAND) and esophagogastric cancer (REAL-3) (see Table 2) [34] [40]. The 
role of adjuvant EGFR inhibition in advanced esophagogastric cancer is being evaluated in a NCI non-rando- 
mized phase II study (NCT01360086, perioperative cisplatin/5-FU with cetuximab). 
Although phase II studies in unselected populations were promising, the S0205 phase III study of cetuximab in 
advanced pancreatic cancer was negative [35]. However, both cetuximab and panitumumabin combination with 
cytotoxic agents have demonstrated benefit in several phase II studies in advancedcholangiocarcinoma [47]- 
[50]. 
Initial phase II studies demonstrated tolerability of cetuximab when added to chemotherapy in HCC [51] [52]. 
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Table 2. Published phase III trials of monoclonal antibodies in GI malignancies.                                     
Agent  
(Trade name,  
Sponsors) 
Study  
Reference 
Disease Type (No. of Evaluable  
Patients) 
Study Design  
and Endpoints 
Dose and  
Schedule Response Rate (%) PFS and OS 
Cetuximab 
(Erbitux®, 
ImClone LLC  
and Eli Lilly) 
NCIC 
CTG/ 
AGITG 
CO.17 
(CA225025) 
[20] [21] 
2nd line relapsed/ 
refractorymCRCagainst  
BSC (572 evaluable) 
Initial enrollment (572): 
• cetuximab+BSC (287) vs.  
BSC (285) 
Repeat analysis: 
By KRAS mutation status (394): 
• KRAS mutant (164, 41.6%):  
Cetuximab + BSC 40.9% vs.  
BSC 42.3% 
• KRAS WT (230, 58.4%):  
Cetuximab+BSC 59.1% vs.  
BSC 57.7% 
By arm: 
• Cetuximab+BSC (198): WT  
58.4% vs. mutant 41.6% 
• BSC (196): WT 58.4% vs.  
mutant 41.6% 
Randomized 
open-label  
phase III trial of  
BSC +/− weekly  
cetuximab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
Cetuximab: 
IV cetuximab  
400 mg/m2  
induction  
followed by  
maintenance IV  
cetuximab 250  
mg/m2 qweekly 
Initial analysis (C vs.  
BSC, all analyses  
significant): 
• RR: 8% (all PR)  
vs. 0% 
• Disease  
stabilization:  
39.4% (PR/SD)  
vs. 10.9% (SD) 
 
Repeat analysis by  
KRAS mutation status  
(C vs. BSC): 
• Not reported 
Initial analysis (C vs.  
BSC): 
• OS: 4.6 mths vs.  
6.1 mths 
• PFS: unreported 
Repeat analysis by  
KRAS mutation  
status (C vs. BSC): 
KRAS mutant: 
• OS: 4.6 mths vs. 
4.5 mths 
• PFS: 1.8 mths vs. 
1.8 mths 
KRAS WT 
• OS: 4.8 mths vs. 
9.5 mths 
• PFS: 1.9 mths vs. 
3.7 mths 
CRYSTAL 
[22] [23] 
[26] 
1st line mCRC treated with  
FOLFIRI (1198 evaluable) 
 
Initial enrollment (1198): 
• FOLFIRI/C (599) vs.  
FOLFIRI (599) 
 
Subgroupanalysis: 
By KRAS mutation status (540): 
• KRAS WT 64.4% vs. mutant  
35.6% 
By arm: 
• FOLFIRI+C: 66.9% WT vs.  
mutant 33.1% 
• FOLFIRI: 62.1% WT vs.  
mutant 37.9% 
Randomized  
open-label phase  
III trial of 2  
weekly FOLFIRI 
+/− weekly  
cetuximab 
 
Primary: PFS 
Secondary: OS,  
RR 
FOLFIRI: 
IV irinotecan  
180 mg/m2 D1,  
IV leucovorin,  
IV 5-FU bolus  
400 mg/m2 D1 
with 2400  
mg/m2 46 hr 
infusion 
 
FOLFIRI +/−  
cetuximab: 
Cetuximab as  
above +  
FOLFIRI 
Initial analysis  
(FOLFIRI vs.  
FOLFIRI/C): 
• RR 38.7% vs.  
46.9% 
 
Subgroup analysis by  
KRAS mutation status  
(FOLFIRI vs.  
FOLFIRI/C): 
• KRAS mutant:  
40.2% vs. 36.2% 
• KRAS WT: 53.2%  
vs. 59.3% 
Initial analysis  
(FOLFIRI vs.  
FOLFIRI/C): 
• OS: 18.6 mths  
vs. 19.9 mths 
• PFS: 8.0 mths vs  
8.9 mths 
Subgroup analysis by  
KRAS mutation  
status: 
KRAS mutant  
(FOLFIRI vs.  
FOLFIRI/C): 
• OS: 17.7 mths  
vs. 17.5 mths 
• PFS: 8.1 mths vs.  
7.6 mths 
KRAS WT  
(FOLFIRI vs.  
FOLFIRI/C) 
• OS: 21.0 mths  
vs. 24.9 mths 
• PFS: 8.7 mths vs.  
9.9 mths 
OPUS (EMR 
62 202-047) 
[24]-[26] 
1st line mCRC treated with  
FOLFOX-4 (337 evaluable) 
 
Initial enrollment (337): 
• FOLFOX-4 (168) vs.  
FOLFOX-4/C (169) 
 
Subgroupanalysis: 
By KRAS mutation status (315): 
• KRAS WT 56.8% vs. mutant  
43.2% 
By arm: 
• FOLFOX-4 (156): 62.2%  
WT vs. 37.8% mutant 
• FOLFOX-4/C (159): 51.6%  
WT vs. 48.4% mutant 
Randomized  
open-label phase  
II trial of 2  
weekly  
FOLFOX-4 +/−  
weekly  
cetuximab 
 
Primary: RR 
 
Secondary: rate  
of curative  
metastatic  
surgery, DCR,  
OS, PFS 
FOLFOX-4: 
IV oxaliplatin  
85 mg/m2 D1,  
IV leucovorin,  
IV 5-FU bolus  
400 mg/m2 D1  
with 600  
mg/m2 22 hr  
infusion 
 
FOLFOX-4  
+/− cetuximab: 
Cetuximab as  
above +  
FOLFOX-4 
Initial analysis of RR  
(FOLFOX-4 vs.  
FOLFOX-4/C: 
• 36% vs. 46% 
Initial analysis of DCR 
(FOLFOX-4 vs.  
FOLFOX-4/C): 
• 81% vs. 85% 
Subgroup analysis of  
RR by KRAS mutation  
status (FOLFOX-4 vs.  
FOLFOX-4/C): 
• KRAS mutant:  
49% vs. 33% 
• KRAS WT: 37%  
vs. 61% 
Subgroup analysis of  
DCR by KRAS  
mutation status  
(FOLFOX-4 vs.  
FOLFOX-4/C): 
• KRAS mutant:  
85% vs. 85% 
• KRAS WT: 78%  
vs. 92% 
Initial analysis  
(FOLFOX-4 vs.  
FOLFOX-4/C): 
• Median PFS: 7.2  
mths vs. 7.2 mths 
Subgroup analysis by  
KRAS mutation  
status: 
KRAS mutant  
(FOLFOX-4 vs.  
FOLFOX-4/C): 
• Median PFS: 8.6  
mths vs. 5.5 mths 
• Median OS: 17.5  
mths vs. 13.4  
mths 
KRAS WT  
(FOLFOX-4 vs.  
FOLFOX-4/C) 
• Median PFS: 7.2  
mths vs. 8.3 mths 
• Median OS: 18.5  
mths vs. 22.8  
mths 
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Continued 
Cetuximab 
(Erbitux®, 
ImClone LLC  
and Eli Lilly) 
MRC COIN 
[27] 
1st line mCRC treated with  
FOLFOX-6/XELOX 
(OPTIMOX-2 regimenevaluated  
in arm C reportedseparately)  
(1630 evaluable) 
 
Initial enrollment (1630): 
• FOLFOX-6/XELOX (815)  
vs.  
FOLFOX-6+C/XELOX+C 
(815) 
 
Subgroupanalysis: 
By KRAS mutation status  
(1316): 
• KRAS/NRAS WT 55.4% vs. 
mutant 44.6% 
By arm: 
• FOLFOX-6/XELOX (648):  
56.6% WT vs. 41.4% mutant 
(2.0% BRAF) 
• FOLFOX-6+C/XELOX+C  
(668): 54.2% WT vs. 44.5%  
mutant (1.3% BRAF) 
Randomized  
open-label phase  
III trial of  
FOLFOX-6/ 
XELOX 
(FOLFOX-6 
2 weekly,  
XELOX 3  
weekly) +/−  
weekly  
cetuximab 
 
Primary: OS 
 
Secondary: PFS 
FOLFOX-6: 
IV oxaliplatin  
85 mg/m2 D1,  
IV leucovorin,  
IV 5-FU bolus  
400 mg/m2 D1  
with 2400  
mg/m2 46 hr 
infusion 
 
XELOX: IV  
oxaliplatin 85  
mg/m2 D1 +  
capecitabine  
850 mg/m2  
twice daily 
 
FOLFOX-6/ 
XELOX +/− 
cetuximab: 
Cetuximab as  
above +  
FOLFOX-4/ 
XELOX 
Analysis of ORR by  
KRAS mutation status  
(FOLFOX-6/XELOX 
vs.  
FOLFOX-6+ 
C/XELOX+C) 
• KRAS WT: 57%  
vs. 64% 
Analysis by KRAS  
mutation status: 
KRAS mutant  
(FOLFOX-6/ 
XELOX vs.  
FOLFOX-6+ 
C/XELOX+C) 
• Median PFS: not  
reported 
• Median OS: 14.8  
mths vs. 13.6  
mths 
 
KRAS WT  
(FOLFOX-6/XELO
X vs. FOLFOX-6+ 
C/XELOX+C) 
• Median PFS: 8.6  
mths vs. 8.6 mths 
• Median OS: 17.9  
mths vs. 17.0  
mths 
NORDIC-VI
I [28] 
1st line mCRC treated with  
continuous/intermittent FLOX  
(566 evaluable) 
 
Initial enrollment (566): 
• FLOX (A-185) vs.  
FLOX+C (B-194) vs.  
intermittent FLOX+C  
(C-187) 
 
Subgroupanalysis: 
By KRAS mutation status (498): 
• KRAS WT 61% vs. mutant  
39% 
By BRAF mutation status (457): 
• BRAF WT 88% vs. mutant  
12% 
By arm: 
• KRAS mutant: FLOX (37%  
mutant) vs. FLOX+C (43%  
mutant) vs. intermittent  
FLOX+C (37% mutant) 
• BRAF mutant: FLOX (13%  
mutant) vs. FLOX+C (13%  
mutant) vs. intermittent  
FLOX+C (10% mutant) 
Randomized  
open-label phase  
III trial of  
continuous/  
intermittent 
FLOX +/−  
weekly  
cetuximab 
 
Primary: PFS 
 
Secondary: OS,  
ORR 
Continuous  
FLOX: 
IV oxaliplatin  
85 mg/m2 D1,  
IV leucovorin,  
IV 5-FU bolus  
500 mg/m2 D1 
 
Cetuximab as  
above 
Overall analysis of  
ORR (FLOX vs.  
FLOX+C vs.  
intermittent 
FLOX+C): 
• 41% vs. 49% vs.  
47% 
Overall analysis  
(FLOX vs. FLOX+C  
vs. intermittent  
FLOX+C) 
• Median PFS: 7.9  
mths vs. 8.3 mths  
vs. 7.3 mths 
• Median OS: 20.4  
mths vs. 19.7  
mths vs. 20.3  
mths 
 
Analysis by KRAS  
mutation status: 
KRAS WT 
• PFS/OS: No  
difference 
 
KRAS mutant 
• PFS: Trend  
towards  
improved PFS  
with cetuximab,  
no significant  
difference. 
• OS: No  
significant  
difference 
EPIC [29] 2nd line mCRCafterfailing  
FOLFOX in  
combinationwithirinotecan (1298 
evaluable) 
 
Initial enrollment (1298): 
• I (650) vs. I/C (648) 
 
Subgroup analysis by KRAS  
mutation status: 
• Not reported 
Randomized  
multi-center  
open-label phase 
III trial of 3  
weekly irinotecan  
+/− cetuximab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
I +/−  
cetuximab: 
 
IV irinotecan  
350 mg/m2  
q3 weekly 
 
Cetuximab as  
above 
Initial analysis of RR  
(I vs. I/C): 
• 4.2% vs. 16.4% 
Subgroup analysis by  
KRAS mutation status: 
• Not reported 
Initial analysis (I vs.  
I/C): 
• OS: 10.0 mths  
vs. 10.7 mths 
• PFS: 2.6 mths vs.  
4.0 mths 
 
Subgroup analysis by  
KRAS mutation  
status: 
• Not reported 
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Continued 
Cetuximab 
(Erbitux®, 
ImClone LLC  
and Eli Lilly) 
ASPECCT 
[30] 
Relapsed/refractory KRAS WT  
mCRC (1010 evaluable) 
Randomized  
non-inferiority  
multi-center  
open-label phase  
III trial of  
2-weekly  
panitumumab vs.  
weekly  
cetuximab 
 
Primary: OS  
(non-inferiority) 
 
Secondary: PFS,  
RR 
Panitumumab: 
IV  
panitumumab  
6 mg/m2  
q2 weekly 
 
Cetuximab as  
above 
Not reported Initial analysis: 
• OS: HR 0.966  
(95% CI 0.839  
- 1.113,  
non-inferiority  
boundary met) 
• PFS/RR not  
reported 
FIRE-3 
[31] 
1st line KRAS exon 2 WT  
mCRC in combinationwith  
FOLFIRI (735 evaluable) 
Randomized  
multi-center  
open-label phase  
III trial of  
FOLFIRI/cetuxi 
mab (arm A) vs.  
FOLFIRI/bevaci 
zumab (arm B) 
 
Primary: ORR 
FOLFIRI as  
above 
 
Cetuximab as  
above 
 
Bevacizumab: 
IV 
bevacizumab  
5 mg/kg q2  
weekly 
Initial analysis of RR  
(FOLFIRI/C vs.  
FOLFIRI/B): 
• 62% vs. 57%  
(non-significant) 
 
Initial analysis of  
PFS/OS (FOLFIRI/C 
vs. FOLFIRI/B): 
• Median PFS:  
10.3 mths vs.  
10.4 mths  
(non-significant) 
• Median OS: 28.8  
mths vs. 25.0  
mths  
(significant) 
NCCTG 
N0147 [32] 
Adjuvant CRC in  
combinationwith FOLFOX-6 in  
resected stage III CRC (2686  
enrolled/randomized,  
treatmenthalted and trial  
closedafter 2580 treated) 
 
Initial enrollment (2686): 
• FOLFOX-6 (1337) vs.  
FOLFOX-6/C (1349) 
 
Subgroupanalysis: 
By KRAS mutation status  
(2580): 
• KRAS WT 72.2% vs. mutant  
27.8% 
By arm: 
• FOLFOX-6: KRAS WT  
70.8% vs. mutant 29.2% 
• FOLFOX-6/C: KRAS WT  
73.6% vs. mutant 26.4% 
Randomized  
multi-center  
open-label phase  
III trial of  
adjuvant 
FOLFOX-6 +/−  
cetuximab in  
stage III CRC  
following 
resection 
 
Primary: DFS 
 
Secondary: OS,  
TTR 
FOLFOX-6 as  
above 
 
Cetuximab as  
above 
Not applicable Analysis by mutation  
status (FOLFOX-6  
vs. FOLFOX-6/C) 
KRAS mutant 
• 3-year DFS:  
67.1% vs. 65.0% 
• OS: 87.9% vs.  
82.7% 
• TTR: 67.9% vs.  
67.0% 
 
KRAS WT 
• 3-year DFS:  
74.6% vs. 71.5% 
• OS: 87.3% vs.  
85.6% 
• TTR: 76.9% vs.  
74.4% 
 
BRAF mutant 
• 3-year DFS:  
67.3% vs. 68.9% 
• OS: 74.8% vs.  
73.7% 
• TTR: 71.2% vs.  
71.9% 
 
PETACC-8 
[33] 
Adjuvant CRC in  
combination with FOLFOX-4 in  
resected stage III CRC (2344  
randomized) 
 
Subgroupanalysis: 
By KRAS mutation status (2344): 
• KRAS WT 68.3% vs. mutant  
31.7% 
By arm: 
• FOLFOX-6: Not reported 
• FOLFOX-6/C: Not reported 
Randomized  
multi-center  
open-label phase  
III trial of  
FOLFOX-4 +/−  
cetuximab 
 
Primary: DFS 
 
Secondary: Not  
reported 
FOLFOX-4 as  
above 
 
Cetuximab as  
above 
Not applicable Analysis by mutation  
status (FOLFOX-4  
vs. FOLFOX-4/C) 
KRAS mutant 
• DFS/OS: No  
significant  
difference 
 
KRAS WT 
• DFS: HR 1.05 
• OS: HR 1.09 
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 EXPAND 
[34] 
1st line advancedgastric cancer  
in combination with  
cisplatin/capecitabine (882  
evaluable) 
Randomized  
multi-center  
open-label phase  
III trial of  
cisplatin/capecita 
bine (CX) +/−  
cetuximab 
 
Primary: PFS 
 
Secondary: OS,  
RR 
Cisplatin/ 
capecitabine  
(CX): 
IV cisplatin  
80 mg/m2 D1 
only + oral  
capecitabine  
1000 mg/m2 
twice daily  
D1-D15  
q3 weekly 
 
Cetuximab as  
above 
Analysis of RR (CX  
vs. CX/C): 
• RR (CR/PR): 29%  
vs. 30% 
• DCR  
(CR/PR/SD): 71%  
vs. 73% 
Analysis of PFS/OS  
(CX vs. CX/C): 
• Median PFS: 5.6  
mths vs. 4.4 mths 
• Median OS: 10.7  
mths vs. 9.4 mths 
S0205 
[35] 
1st line advancedpancreatic  
cancer in combination with  
gemcitabine (743 evaluable) 
Randomized  
multi-center  
open-label phase  
III trial of  
gemcitabine (G)  
+/− cetuximab 
 
Primary: OS 
 
Secondary: OR,  
PFS 
Gemcitabine: 
IV gemcitabine  
1000 mg/m2 
weekly 7-on,  
1-off 
 
Cetuximab as  
above 
Initial analysis of RR  
(G vs. G/C): 
• RR (CR/PR): 14%  
vs. 12% 
• DCR  
(CR/PR/SD): 30%  
vs. 37% 
Initial analysis of  
PFS/OS (G vs. G/C): 
• Median PFS: 3.0  
mths vs. 3.4 mths 
• Median OS: 5.9  
mths vs. 6.3 mths 
Panitumumab 
(Vectibix®, 
Illumina and  
Amgen) 
Van Cutsem 
E, et al. [36] 
2nd line  
relapsed/refractorymCRC 
against BSC (463evaluable) 
 
Initial enrollment (463): 
• panitumumab+BSC (231)  
vs. BSC (232) 
Randomized  
open-label phase  
III trial of BSC  
+/− 2-weekly  
panitumumab 
 
Primary: PFS 
 
Secondary: RR,  
OS 
Panitumumab: 
IV 
panitumumab  
6 mg/m2 
q2 weekly 
Initial analysis (BSC  
vs. P): 
• RR: 0% vs. 10%  
(all PR) 
• DCR: 10% (SD)  
vs. 27% (PR/SD) 
Initial analysis (BSC  
vs. P): 
• OS: HR 1.00 
• PFS: 8 weeks vs.  
7.3 weeks 
PRIME 
[37] 
1st line mCRC in combination  
with FOLFOX-4 (1183) 
Initial enrollment (1183  
evaluable): 
• FOLFOX-4 (590) 
• FOLFOX-4/P (593) 
By KRAS mutation status  
(1096): 
• FOLFOX-4 (550) 
• FOLFOX-4/P (546) 
By arm: 
• FOLFOX-4: KRAS WT  
(60.2%) vs. KRAS mutant  
(39.8%) 
• FOLFOX-4/P: KRAS WT  
(59.5%) vs. KRAS mutant  
(40.5%) 
Randomized  
multi-center  
open-label phase  
III trial of 1st line  
FOLFOX-4 vs.  
FOLFOX-4/P 
 
Primary: PFS 
 
Secondary: OS,  
ORR 
FOLFOX-4  
+/− P: 
FOLFOX-4 as  
above 
 
Panitumumab  
as above 
Analysis by KRAS  
mutation status  
(FOLFOX-4 vs.  
FOLFOX-4/P): 
• KRAS mutant:  
48% vs. 55% 
• KRAS WT: 40%  
vs. 40% 
Analysis by KRAS  
mutation status  
(FOLFOX-4 vs.  
FOLFOX-4/P): 
KRAS mutant: 
• Median OS: 19.3  
mths vs. 15.5  
mths 
• Median PFS: 8.8  
mths vs. 7.3 mths 
 
KRAS WT: 
• Median OS: 19.7  
mths vs. 23.9  
mths 
• Median PFS: 8.0  
mths vs. 9.6 mths 
181 [38] 2nd line relapsed/refractory  
mCRC after failing  
priorchemotherapy (1186  
evaluable) 
Initial enrollment (1186): 
• FOLFIRI (595) 
• FOLFIRI/P (591) 
By KRAS mutation status  
(1083): 
• FOLFIRI (542) 
• FOLFIRI/P (541) 
By arm: 
• FOLFIRI: KRAS WT  
(54.2%) vs. KRAS mutant  
(45.8%) 
• FOLFIRI/P: KRAS WT  
(56.0%) vs. KRAS mutant  
(44.0%) 
Randomized  
multi-center  
open-label phase  
III trial of 2nd  
line FOLFIRI vs.  
FOLFIRI/P 
 
Primary: PFS and  
OS 
 
Secondary: ORR 
FOLFIRI  
+/− P: 
 
FOLFIRI as  
above 
 
Panitumumab  
as above 
Analysis by KRAS  
mutation status  
(FOLFIRI vs.  
FOLFIRI/P): 
• KRAS mutant:  
35% vs. 10% 
• KRAS WT: 13%  
vs. 14% 
Analysis by KRAS  
mutation status  
(FOLFIRI vs.  
FOLFIRI/P): 
KRAS mutant: 
• Median OS: 11.1  
mths vs. 11.8  
mths 
• Median PFS: 4.9  
mths vs. 5.0 mths 
 
KRAS WT: 
• Median OS:  
12.5 mths vs.  
14.5 mths 
• Median PFS: 3.9  
mths vs. 5.9 mths 
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Panitumumab 
(Vectibix®, 
Illumina and  
Amgen) 
PICCOLO 
[39] 
2nd line mCRCafterfailing 5-FU  
and/oroxaliplatin in  
combination with irinotecan in  
KRAS WT patients (460  
evaluable) 
 
Initial enrollment (460): 
• I (230) vs. I/P (230) 
Randomized  
multi-center  
open-label phase  
III trial of 2nd  
line irinotecan  
+/−  
panitumumab  
in KRAS WT  
patients 
 
Primary: OS 
 
Secondary: PFS,  
RR 
I:IV irinotecan  
350 mg/m2  
q3 weekly 
 
Panitumumab:  
IV  
panitumumab 
9 mg/m2  
q3 weekly 
Analysis (I vs. I/P): 
• RR: OR of  
response 4.12 
Analysis (I vs. I/P): 
• Primary OS  
analysis after  
246 deaths: 10.5  
mths vs. 10.4  
mths 
• Final OS  
analysis: 10.9  
mths vs. 10.4  
mths 
• PFS: HR 0.78 
REAL3 
[40] 
1st line advance  
desophagealadenoCA in  
combination with EOC (553  
evaluable) 
 
Initial enrollment (553): 
• EOC (275) vs. EOC/P (278) 
Randomized  
multi-center  
open-label phase  
III trial of 1st line  
EOC +/− 
panitumumab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
EOC: IV  
epirubicin 50  
mg/m2 D1, IV  
oxaliplatin  
100 mg/m2 D1,  
oral  
capecitabine  
1000 mg/m2  
twice daily  
D1-D21 
 
Panitumumab: 
IV  
panitumumab 
9 mg/m2  
q3 weekly 
Analysis (EOC vs.  
EOC/P): 
• RR: 42% vs. 46% 
Analysis (EOC vs.  
EOC/P): 
• PFS: 7.4 mths vs.  
6.0mths 
• 1-year PFS: 21%  
vs. 20% 
• OS analysis after  
251 deaths: 11.3 
mths vs. 8.8 mths 
• 1-year OS: 46%  
vs. 33% 
ASPECCT 
[30] 
Seeabove 
Bevacizumab 
(Avastin®, 
Genentech) 
Hurwitz 
et al. 
[56] [57] 
1st line mCRC in combination  
with IFL (813 evaluable) 
 
Initial enrollment (813): 
• IFL/placebo (402) vs. IFL/B  
(411) 
Randomized 
multi-center  
placebo- 
controlled phase 
III trial of 1st line 
IFL +/−  
bevacizumab 
 
Primary: OS 
 
Secondary: PFS, 
RR 
IFL (given  
weekly for 4  
weeks, cycles  
repeat 
q6weekly: 
IV irinotecan  
125 mg/m2 
qweekly, IV  
5-FU 500  
mg/m2  
qweekly, IV  
leucovorin  
20 mg/m2 
qweekly 
 
Bevacizumab:  
IV  
bevacizumab  
5 mg/m2 
q2 weekly 
Analysis (IFL vs.  
IFL/B): 
• RR: 34.8% vs.  
44.8% 
Analysis (IFL vs.  
IFL/B): 
• PFS: 6.2 mths  
vs. 10.6 mths 
• OS: 15.6 mths  
vs. 20.3 mths 
E3200 [58] 2nd line mCRCafterfailing 5-FU  
and/or irinotecan in combination  
with FOLFOX-4 (820 evaluable) 
 
Initial enrollment (820): 
• FOLFOX-4 (291) vs.  
FOLFOX-4/B (286) vs. B  
(243) 
Randomized 
multi-center 
open-label phase 
III trial of 2nd line 
FOLFOX +/−  
bevacizumab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
FOLFOX-4 as  
above 
 
Bevacizumab:  
IV  
bevacizumab  
10 mg/m2  
q2 weekly 
Analysis (FOLFOX-4  
vs. FOLFOX-4/B vs.  
B): 
• RR: 8.6% vs. 22.7%  
vs. 3.3% 
Analysis  
(FOLFOX-4 vs.  
FOLFOX-4/B  
vs. B): 
• PFS: 4.7 mths  
vs. 7.3 mths vs.  
2.7 mths 
• OS: 10.8 mths  
vs. 12.9 mths  
vs. 10.2 mths 
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 NO16966 
[59] 
1st line mCRC 2 × 2 factorial  
combination with FOLFOX-4  
or XELOX (1401 randomized,  
1400 evaluable) 
 
Initial enrollment (1401): 
• FOLFOX-4 (351) vs.  
FOLFOX-4/B (349) vs.  
XELOX (350) vs.  
XELOX/B (350) 
Randomized 
multi-center 
placebo- 
controlled 2 × 2  
factorial phase III  
trial of 1st line  
FOLFOX/XELO 
X +/−  
bevacizumab 
 
Primary: PFS 
 
Secondary: 
on-treatment 
PFS, OS, RR 
FOLFOX-4 as  
above 
XELOX: IV  
oxaliplatin  
130 mg/m2 D1  
+ oral  
capecitabine  
1000 mg/m2  
twice daily  
D1-D15 q3  
weekly 
Bevacizumab:  
IV  
bevacizumab  
5 mg/m2  
q2 weekly (with  
FOLFOX-4) or  
7.5 mg/m2  
q3 weekly (with  
XELOX) 
Analysis  
(FOLFOX-4/XELOX  
vs. FOLFOX-4/ 
XELOX + B): 
• Investigator-assesse 
d RR: 49% vs. 47% 
• Independent  
response review  
committee RR: 38%  
vs. 38% 
Analysis 
(FOLFOX-4/ 
XELOX vs.  
FOLFOX-4/ 
XELOX + B): 
• PFS: 8.0 mths  
vs 9.4 mths 
• On-treatment  
PFS: 7.9 mths  
vs 10.4 mths 
• OS: 19.9 mths  
vs. 21.3 mths 
TML/ 
ML18147 
[60] 
Continuation bevacizumab in  
mCRC with switch  
chemotherapy in 1st progression  
(819 evaluable) 
 
Initial enrollment (819): 
• Switch chemotherapy (410)  
vs. switch chemotherapy + B  
(409) 
Randomized 
multi-center 
open-label phase  
III trial of switch  
chemotherapy  
+/− bevacizumab 
maintenance 
 
Primary: OS 
 
Secondary: PFS,  
on-treatment 
PFS, RR 
FOLFOX-4, 
XELOX, 
FOLFIRI, 
XELIRI as  
above 
Bevacizumab: 
IV  
bevacizumab 5  
mg/m2 q2  
weekly (with  
FOLFOX-4/ 
FOLFIRI) or  
7.5 mg/m2  
q3 weekly (with  
XELOX/ 
XELIRI) 
Analysis (switch  
chemotherapy vs.  
switch  
chemotherapy+B): 
 
• RR (PR/CR): 3.9%  
vs. 5.4% 
• DCR (SD/PR/CD):  
54.2% vs. 68.1% 
Analysis (switch  
chemotherapy vs.  
switch  
chemotherapy+B): 
• On-treatment  
PFS: 4.0 vs. 5.7  
mths 
• OS: 9.8 mths  
vs. 11.2 mths 
• Median OS  
from start of 1st  
line therapy:  
22·5 mths vs.  
23.9 mths 
TRIBE 
[61] 
1st line mCRC combination  
bevacizumab with FOLFIRI vs.  
FOLFOXIRI (508 evaluable) 
 
Initial enrollment (508): 
• FOLFIRI/B vs.  
FOLFOXIRI/B 
Randomized  
multi-center  
open-label phase  
III trial of  
FOLFIRI/B vs.  
FOLFOXIRI/B 
 
Primary: PFS 
 
Secondary: OS,  
RR, R0 resection  
rate 
FOLFIRI/B as  
above. 
FOLFOXIRI/ 
B: IV  
oxaliplatin  
85 mg/m2 D1,  
IV irinotecan  
165 mg/m2 D1,  
IV leucovorin,  
IV 5-FU  
3200 mg/m2  
48 hr infusion 
Bevacizumab:  
IV  
bevacizumab 5  
mg/m2  
q2 weekly 
Analysis (FOLFIRI/B  
vs. FOLFOXIRI/B): 
• RR (PR/CR): 53%  
vs. 65% 
Analysis 
(FOLFIRI/B vs.  
FOLFOXIRI/B): 
• Median PFS:  
9.7 mths vs.  
12.2 mths 
• Median OS:  
25.8 mths vs.  
31.0 mths 
• R0 resection  
rate: 12% vs.  
15% 
NSABP 
C-08 
[62] 
Adjuvant bevacizumab in stage  
II/III resected CRC in  
combination with  
FOLFOX-6 (2672 evaluable) 
 
Initial enrollment (2672): 
• FOLFOX-6 (1338) vs.  
FOLFOX-6/B (1334) 
Randomized 
multi-center 
open-label phase  
III trial of  
FOLFOX-6 vs.  
FOLFOX-6/B in  
resected stage  
II/III CRC 
 
Primary: DFS 
 
Secondary: OS 
FOLFOX-6 as  
above for 6  
months 
 
Bevacizumab  
as above for 1  
year 
Not applicable Analysis 
(FOLFOX-6 vs.  
FOLFOX-6/B): 
• Median DFS:  
HR 0.89 (non- 
significant) 
• 3-year DFS:  
75.5% vs.  
77.4% 
• 3-year DFS  
(stage II):  
84.7% vs.  
87.4% 
• 3-year DFS  
(stage III):  
72.4% vs.  
74.2% 
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 AVANT 
[63] 
Adjuvant bevacizumab in stage 
II/III resected CRC in  
combination with FOLFOX-6  
[3451 evaluable, 2861 (83%)  
stage III] 
 
Initial enrollment (3451): 
• FOLFOX-4 (1151/955 stage  
III) vs. FOLFOX-4/B  
(1155/960 stage III) vs.  
XELOX/B (1145/952 stage  
III) 
Randomized  
multi-center  
open-label phase  
III trial of  
FOLFOX-4 vs.  
FOLFOX-4/B vs.  
XELOX/B in  
resected stage  
II/III CRC 
 
Primary: DFS  
(stage III  
patients) 
FOLFOX-4,  
FOLFOX-4/B  
and XELOX/B  
as above 
Not applicable Analysis: 
• DFS: HR 1.17  
(FOLFOX-4  
vs.  
FOLFOX-4/B)  
(non- 
significant) 
• DFS: HR 1.07  
(FOLFOX-4  
vs. XELOX/B) 
(non- 
significant) 
• OS: HR 1.27  
(FOLFOX-4 
vs.  
FOLFOX-4/B) 
(significant) 
• OS: HR 1.15  
(FOLFOX-4 
vs. XELOX/B)  
(non- 
significant) 
FIRE-3 
[31] 
Seeabove 
AVAGAST 
[64] 
1st line  
metastaticgastriccarcinoma  
in combination with  
cisplatin/capecitabine (774  
evaluable) 
 
Initial enrollment (774): 
• CX (387) vs. CX/B (387) 
Randomized 
international 
multi-center 
placebo- 
controlled phase  
III trial of  
cisplatin/ 
capecitabine 
(CX) +/− 
bevacizumab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
Cisplatin/ 
capecitabine  
(CX) as above 
 
Bevacizumab: 
IV  
bevacizumab 
7.5 mg/m2  
q3 weekly 
Analysis (CX vs.  
CX/B): 
• RR: 37.4% vs.  
46.0% (significant) 
Analysis (CX vs.  
CX/B): 
• Median PFS:  
5.3 mths vs 6.7  
mths  
(significant) 
• Median OS:  
10.1 mths vs.  
12.1 mths (non- 
significant) 
AVATAR 
[65] 
1st line  
metastaticgastriccarcinoma  
in combination with  
cisplatin/capecitabine in Asian  
patients (202 evaluable) 
 
Initial enrollment (202): 
• CX (102) vs. CX/B (100) 
Randomized  
multi-center  
placebo- 
controlled  
phase III trial of 
cisplatin/ 
capecitabine  
(CX) +/−  
bevacizumab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
Cisplatin/ 
capecitabine  
as above 
 
Bevacizumab 
as above 
Analysis (CX vs.  
CX/B): 
• RR (PR/CR): 33.7%  
vs. 40.7% 
• DCR (PR/CR/SD):  
72.1% vs. 75.3% 
Analysis (CX vs.  
CX/B): 
• Median PFS:  
6.0 mths vs 6.3  
mths 
• Median OS:  
11.4 mths vs.  
10.5 mths 
CALGB 
80303 [66] 
1st line  
metastaticpancreaticcarcinoma in  
combination with gemcitabine  
(535 evaluable) 
 
Initial enrollment (535): 
• G (256) vs. G/B (279) 
Randomized  
multi-center  
placebo- 
controlled phase  
III trial of  
gemcitabine (G)  
+/− bevacizumab 
 
Primary: OS 
 
Secondary: PFS,  
RR 
Gemcitabine (G 
vs. CX/B): 
IV gemcitabine  
1000 mg/m2  
D1, 8 and 15  
q4weekly 
 
Bevacizumab: 
IV  
bevacizumab  
10 mg/m2 D1  
and 15  
q4weekly 
Analysis (G vs. G/B): 
• RR (PR/CR): 10%  
vs. 13% 
Analysis (G vs.  
G/B): 
• Median PFS:  
3.8 mths vs 2.9  
mths 
• Median OS: 5.9  
mths vs. 5.8  
mths 
D. Davar, W. Sun 
 
 632 
Continued 
Ramucirumab 
(Cyramza®, Eli 
Lilly) 
REGARD 
(I4T-IE- 
JVBD) [67] 
2nd line relapsed/ 
refractorymetastaticesopha  
gogastriccarcinoma against BSC 
(355 evaluable) 
 
Initial enrollment (535): 
• BSC (117) vs. BSC/R (238) 
Randomized 
international 
placebo- 
controlled  
phase III trial  
of BSC +/  
ramucirumab 
 
Primary: OS 
 
Secondary: PFS,  
12-week, RR 
Ramucirumab: 
IV  
ramucirumab  
8 mg/kg  
q2 weekly 
Analysis (BSC vs.  
BSC/R): 
• RR (PR/CR): 3% vs  
3% 
• DCR (PR/CR/SD):  
23% vs. 49% 
Analysis (BSC vs.  
BSC/R): 
• Median OS: 3.8  
mths vs. 5.2  
mths 
• 6 month OS  
31.6% vs.  
41.8% 
• 12 month OS  
11.8% vs.  
17.6% 
• Median PFS  
1.3 mths vs. 2.1  
mths 
• Median  
12-week PFS  
15.8% vs.  
40.1% 
RAINBOW 
(I4T-IE- 
JVBE) [68] 
2nd line  
metastaticesophagogastriccarcin
oma  
in combination with paclitaxel  
following progression on 1st line  
platinum- and  
fluoropyrimidine-containingche
motherapy (665 evaluable) 
 
Initial enrollment (665): 
• Paclitaxel (335) vs.  
paclitaxel/R (330) 
 
Randomized  
international 
placebo- 
controlled phase  
III trial of  
paclitaxel +/−  
ramucirumab 
 
Primary: OS 
 
Secondary: PFS,  
12-week, RR 
Paclitaxel: IV  
paclitaxel  
80 mg/m2 D1,  
8, 15 q4 weekly 
 
Ramucirumab 
as above 
Analysis (P vs. P/R): 
• RR: 16% vs. 28% 
Analysis (P vs.  
P/R): 
• Median OS: 7.4  
mths vs. 9.6  
mths 
• Median PFS:  
2.9 mths vs. 4.4  
mths 
Ziv-aflibercept 
(Zaltrap®, 
Regeneron and  
Bayer) 
VELOUR 
[69] 
2nd line mCRC in  
combinationwith FOLFIRI  
following priortreatment with  
oxaliplatin-basedregimens (1226  
evaluable) 
 
Initial enrollment (1226): 
FOLFIRI/placebo (614) vs.  
FOLFIRI/Z (612) 
Randomized 
multi-center 
placebo- 
controlled phase  
III trial of  
FOLFIRI/ 
placebo vs.  
FOLFIRI/Z 
 
Primary: OS 
 
Secondary: RR 
FOLFIRI as  
above  
q2 weekly 
 
Aflibercept: IV  
aflibercept 4  
mg/kg q2 
weekly 
Analysis 
(FOLFIRI/placebo vs.  
FOLFIRI/Z): 
• RR (PR/CR): 11.1%  
vs 19.8% 
Analysis  
(FOLFIRI/placebo 
vs. FOLFIRI/Z): 
• Median OS:  
12.1 mths vs.  
13.5 mths 
• 2 year survival:  
18.7% vs.  
28.0% 
• Median PFS:  
4.7 mths vs. 6.9  
mths 
VANILLA 
[70] 
1st line  
metastaticpancreaticcarcinoma in  
combination with gemcitabine  
(546 evaluable) 
 
Initial enrollment (546): 
• G/placebo (275) vs. G/Z  
(271) 
Randomized  
multi-center  
placebo- 
controlled  
phase III trial of  
G/placebo vs.  
G/Z 
 
Primary: OS 
 
Secondary: PFS,  
RR 
Gemcitabine:  
IV gemcitabine  
1000 mg/m2  
qweekly for 7  
weeks out of 8  
then qweekly  
for 3 weeks out  
of 4 
 
Aflibercept as  
above 
Analysis (G/placebo vs.  
G/Z): 
• RR (PR/CR): Not  
reported 
Analysis 
(G/placebo vs.  
G/Z): 
• Median OS: 7.8  
mths vs. 6.5  
mths 
• 6 mth survival:  
63% vs 54% 
• 12 mth  
survival: 25%  
vs. 21% 
• Median PFS:  
3.7 mths vs. 3.7  
mths 
• 6 mth PFS:  
30% vs. 27% 
• 12 mth PFS:  
4% vs. 3% 
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Trastuzumab 
(Herceptin®, 
Roche) 
TOGA [78] 1st line metastatic HER2+  
GEJ/gastriccarcinoma in  
combination with cisplatin and  
5-FU/capecitabine (CF or CX)  
(584 evaluable) 
 
Initial enrollment (584): 
• Chemotherapy (290) vs.  
chemotherapy/T (294) 
Randomized 
international 
multi-center 
open-label phase  
III trial of  
chemotherapy vs.  
chemotherapy/T 
 
Primary: OS 
 
Secondary: PFS,  
RR 
Chemotherapy 
(CF/CX): 
Cisplatin/5-FU 
(CF): IV  
cisplatin  
80 mg/m2 D1 +  
IV 5-FU  
800 mg/m2  
daily D1-5 
Cisplatin/ 
capecitabine 
(CX) as above 
 
Trastuzumab: 
IV trastuzumab  
8 mg/kg  
induction  
followed  
by maintenance  
IV trastuzumab  
6 mg/kg  
q3 weekly 
Analysis (chemotherapy  
vs. chemotherapy/T): 
• RR (PR/CR): 35%  
vs 47% 
• DCR (PR/CR/SD):  
70% vs. 79% 
Analysis  
(chemotherapy vs.  
chemotherapy/T): 
• Median OS:  
11.1 mths vs.  
13.8 mths 
• Median PFS:  
5.5 mths vs. 6.7  
mths 
PFS—progression-free survival; OS—overall survival; mCRC—metastatic colorectal carcinoma; BSC—best supportive care; RR—response rate; DCR 
—disease control rate. 
 
However, a recent phase II study reported OS results that would be inferior when compared to sorafenib [53]. 
No further phase III evaluation of EGFR inhibition is planned in this disease. 
2.2. VEGF Inhibition: Bevacizumab (Avastin®), Ramucirumab (Cyramza®) and  
Ziv-Aflibercept (Zaltrap®) 
The ability of tumors to induce angiogenesis is a central concept in cancer proliferation [54]. Our understanding 
of tumor angiogenesis and its inhibition has evolved considerably: rather than directly inhibit tumor growth, 
VEGF-inhibition may mainly normalize abnormal tumor vasculature and improve delivery of cytotoxic agents 
[55]. 
Bevacizumab is a humanized monoclonal antibody that binds circulating VEGF-A, preventing its engagement 
with downstream VEGF receptors (VEGFR-1/2/3) with multifarious effects including inhibition of angiogenic 
signaling. Bevacizumab was the first biologic agent approved by the FDA to treat any malignancy in 2004 and 
EMA approval followed in 2005. Approval centered on the results of a front-line randomized phase III study in 
metastatic CRC with the combination of cytotoxic IFL (irinotecan/5-FU/leucovorin) chemotherapy plus bevaci- 
zumab vs. placebo, in which bevacizumab conferred an OS benefit of 4.7 months over IFL alone (20.3 vs. 15.6 
months) [56]. A flurry of trials followed, evaluating bevacizumab’s role in 1st and 2nd line settings with alterna- 
tive chemotherapy combinations and in other diseases (non-small cell lung cancer, renal cell carcinoma, ovarian 
carcinoma, and glioblastomamultiforme). These results are summarized in Table 2 [56]-[69]. 
The aggregate data demonstrated that bevacizumab is preferred in KRAS mutant mCRCpatients population 
since they do not benefit from EGFR inhibition. Mounting evidence supports prolonged duration of anti-VEGF 
therapy in metastatic CRC. NO16966 data suggested further improvement when bevacizumab was continued till 
overt progression and ML18147 confirmed that bevacizumab continuation past progression improved PFS and 
OS [59] [60]. Based on the negative results of AVANT and NSABP C-08, bevacizumabdid not show obvious 
benefit in either overall survival (OS) or disease-free survival(DFS) at the adjuvant setting for resected CRC [62] 
[63]. 
The role of bevacizumab in gastroesophageal cancer treatment has not been approved based on the 2 pub- 
lished large randomized phase III studies (AVAGAST, AVATAR). The AVAGAST study compared chemo- 
therapy versus chemotherapy plus bevacizumab as the first line in patients with metastatic gastric cancer. Al- 
though, the study did not show obvious survival benefit by adding bevacizumab, patients with high baseline 
plasma VEGF-A levels, and low baseline expression of neuropilin-1 showed a trend toward improved overall 
survival [64] [106]. The other study, AVATAR, did not show benefit of bevacizumabadding to the combination 
of capecitabine and cisplatin in Chinese patients with metastatic gastric cancer [65]. A randomized phase III 
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study (ST03) is evaluating the role of adjuvant VEGF inhibition in EGJ/proximal gastric adenocarcinomas. 
Ramucirumab is a fully human monoclonal antibody (IgG1) asVEGFR2 receptor antagonist that prevents the 
binding of VEGF to VEGFR2—the interaction thought to mediate the bulk of VEGF downstream effects. Ra- 
mucirumabmonotherapy modestly improved OS (5.2 months vs. 3.8 months) in 2nd line advanced EGJ/gastric 
carcinoma compared to placebo after prior platinum-containing or fluoropyrimidine-containing chemotherapy 
[67]. Ramucirumab has demonstrated benefit in the 2nd line setting when combined with paclitaxel chemothera- 
py in patients who progressed on prior 1st line platinum- and 5-FU-based combinations (RAINBOW) [68]. The 
median overall survival was 9.6 months for the ramucirumab and paclitaxel combination compared to 7.4 
months for paclitaxel alone (p = 0.0169) with 19% reduction in the risk of death. Prior front-line studies utilizing 
bevacizumab (AVAGAST, AVATAR) were negative, and it is possible that the benefit seen with ramucirumab 
is secondary to the greater interruption of VEGF signaling with ramucirumabcompared to bevacizumab [64] 
[65]. 
For unclear reason, VEGF inhibition has not proved beneficial in pancreatic carcinoma (CALGB 80303-be- 
vacizumab, VANILLA-aflibercept) [66] [70]. 
In contrast to bevacizumab and ramucirumab, ziv-aflibercept (Zaltrap®) is a fusion protein that acts as a de- 
coy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). In vitro studies demonstrated that ziv- 
aflibercept bound VEGF-A with 100-fold greater affinity and more potent blockade of VEGFR-1/VEGFR-2 
than bevacizumab. The phase III VELOUR trial evaluated the combination of ziv-aflibercept and FOLFIRI in 
the second line metastatic CRC after progression on prior oxaliplatin-based therapy and reported modest benefit 
[69]. Data to support the use of ziv-aflibercept in the 1st line setting is lacking—the AFFIRM trial which re-
ported similar PFS between both arms was a non-comparative study that was not powered to evaluate the addi-
tion of ziv-aflibercept to FOLFOX-6 compared to FOLFOX-6; hence the trial is better considered as an evalua-
tion of alternative 1st line VEGF inhibition together with FOLFOX-6 [71] [72]. A phase II trial is evaluating the 
OPTIMOX strategy (FOLFOX-7) in the 1st line setting in combination with aflibercept (NCT01802684, 
VELVET). 
In HCC, bevacizumab has shownimproved survival singly and in combination in multiple phase II studies. 
VEGF inhibition is considered to have a role in the systemic treatment of advanced HCC in addition tosorafenib 
[73] [74]. However, further randomized phase III trials are needed to confirm this result. 
2.3. Monoclonal Antibodies: Her-2/neu Inhibition: Trastuzumab (Herceptin®), 
Pertuzumab (Perjeta®) and Trastuzumab-Emtansine (T-DM1, Kadcyla®) 
HER2/neu encodes the ERBB2 protein, a member of the EGFR family of receptor tyrosine kinases—all of 
which comprise an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. 
HER2 ligand binding activates multiple downstream signals including via the MAPK (RAS/RAF/MEK/ERK), 
PI3K/AKT, STAT, phospholipase C γ and protein kinase C pathways. HER2/neu over expression has been ob- 
served in approximately 15% - 25% of breast cancers and is associated with poorer responses to therapy and a 
clinically aggressive course. HER2/neu over expression occurs at a slightly lower frequency (12% - 22%) in 
esophagogastric malignancies compared to breast cancers although the prognostic implication is unclear [75]- 
[77]. Incidence between esophageal and gastric malignancies is similar; though among gastric cancer sub-types, 
HER2/neu positivity is seen more often with intestinal-type than diffuse-type cancers [78]. For the 7% - 22% of 
patients whose tumors overexpress HER2 by FISH or IHC, the phase III TOGA study was unequivocally posi- 
tive and resulted in regulatory approval for 1st line use (see Table 2) [79]. TOGA’s chemotherapy arm consisted 
of cisplatin with 5-FU or capecitabine, and the addition of trastuzumab to regimens. 
Diminished efficacy to trastuzumab may develop secondary to primary or secondary resistance—with pri-
mary resistance rates as high as 66% - 88% in HER2-overexpressing metastatic breast cancer. Although several 
mechanisms of resistance in breast cancer have been proposed, no data is available in EGJ/gastric carcinomas. 
Pharmacokinetic data from phase I/II breast cancer trials suggests that failure to achieve steady-state levels sec-
ondary to rapid clearance may contribute to primary resistance [80]. HELOISE (NCT01450696) is an interna-
tional phase III study (NCT01450696) evaluating standard (8 mg/kg loading, then 6 mg/kg q3 weekly) versus 
high (8 mg/kg loading, then 10 mg/kg q3 weekly) in advanced HER2+ EGJ/gastric carcinomas. 
Trastuzumabemtansine (T-DM1) is an antibody-drug conjugate consisting of trastuzumab linked to the anti-  
tubulin agent mertansine (DM1). T-DM1 improved survival by 5.8 months compared to lapatinib/capecitabine 
in trastuzumab resistant metastatic breast cancer [81]. In advanced HER2+ EGJ/gastric carcinomas, T-DM1 is 
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being evaluated in combination with physician choice taxane (docetaxel or paclitaxel). The phase II/III study 
(NCT01641939) utilizes a novel adaptive design that will evaluate two schedules of T-DM1 (2.4 or 3.6 mg/kg 
q3 weekly) and pick the phase III dose of T-DM1 depending on the tolerability at 12 weeks. Pertuzumab is a 
humanized monoclonal antibody that inhibits HER2 dimerization, as distinct from trastuzumab. Combined 
HER2 blockade with trastuzumab/pertuzumab was evaluated in both the neoadjuvant (TRYPHAENA) and me- 
tastatic settings (CLEOPATRA) in breast cancer with high pathologic complete response (pCR) rates and sig- 
nificant improvements in OS respectively [82] [83]. Combined HER2 blockade in HER2+ EGJ/gastric carcino-
mas with trastuzumab/pertuzumab is under evaluation in a phase III trial (BO25114, NCT01774786). 
HER2 inhibition is not being evaluated in other GI malignancies. 
2.4. Checkpoint Inhibitors: Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Programmed 
Death-1 (PD-1) 
Peptide antigens presented in association with major histocompatibility proteins (MHC) by antigen-presenting 
cells (APC) to T-cell receptors (TCR) triggers antigen-specific T-cell activation. T-cells have evolved a two-step 
mechanism that requires a second signal to mediate whether the antigen-TCR interaction results in proliferation, 
cytokine secretion, and differentiation or development of tolerance and anergy. T-cell co-stimulatory and 
co-inhibitory signals are thus potent homeostatic mechanisms that maintain a balance between effective immune 
responses and peripheral tolerance. T-cell CD28 is the primary co-stimulatory signal modulator while CTLA-4 
(CD152) is the primary co-inhibitory signal regulator for CD4+ T-helper, CD8+ T-effector and CD25+ Foxp3+ 
regulatory T cells. The functional outcome of the ligand-APC-T-cell interaction depends on the relative en- 
gagement between APC B7-1/B7-2 (CD80/86) and T-cell CD28 versus CTLA-4. 
In addition to CTLA-4, several T-cell surface molecules participate in negative and positive regulation of 
T-cell activation. The exact role of these molecules in T-cell priming, growth and survival and more specifically 
in T-effector function, T-helper differentiation, and memory T-cell sustenance are reviewed elsewhere [84]. 
While CTLA-4 initiates the negative feedback loop in T-cell activation, PD-1 is part of the effector phase of this 
loop. PD-L1 is ubiquitously expressed on tumors and the PD-1/PD-L1 interaction downregulates T-effector re-
sponses possibly through suppression of PI3K/AKT activation [85]. 
CTLA-4 blockade and PD-1 inhibition were thus attractive targets to augment anti-tumor T-cell immunity in 
cancer. Two CTLA-4 inhibitors [ipilimumab (Yervoy, BMS) and tremelimumab (CP-675206)] and several 
PD-1/PD-L1 inhibitors have been developed [nivolumab (BMS-936558, BMS), lambrolizumab (MK-3475, 
Merck) and MPDL3280A (Roche/Genentech/Chugai)] and are in various phases of clinical testing. Of these, 
ipilimumab has been approved for the treatment of metastatic melanoma in both the 1st line and relapsed set- 
tings following successful phase III trials against chemotherapy (dacarbazine) and vaccine (GP-100) compara- 
tors respectively [86] [87]. Despite promising phase II results, a phase III study of tremelimumab in advanced 
melanoma was negative and further interest has stalled [88]. 
Initial evaluation of PD-1 and CTLA-4 inhibition in GI malignancies centered on pancreatic carcinoma but 
was subsequently extended to advanced CRC and HCC [89]. Microsatellite stability is an important prognostic 
marker in CRC: tumors with high-degree microsatellite instability (MSI-H) have a better prognosis than tumors 
with low-degree instability (MSI-L) or stable microsatellite (MSS) status. This may be related, in part, to greater 
immunogenicity associated with MSI-H tumors [90] [91]. Investigational approaches in advanced MSI-H CRC 
include PD-1 (NCT01876511) or PD-1/CTLA-4 combination (NCT01928394, CheckMate 142). Early phase 
studies are evaluating this approach in combination with chemotherapy in advanced pancreatic cancer (NCT- 
01473940-gemcitabine/ipilimumab and NCT01896869-FOLFIRINOX/GM-CSF vaccine) and singly in ad-
vanced HCC (NCT01658878). A summary of the ongoing trials is provided in Table 3. 
2.5. Vaccines 
Cancer vaccines aim to produce persistent anti-tumor immunity that result in prolonged durable responses. Vac- 
cines are classified based on the antigen(s) incorporated—whole cell, protein, peptide, recombinant virus, den- 
dritic cell, and naked DNA. Cancer vaccines have been studied in various settings (adjuvant, neo-adjuvant and 
metastatic) across a gamut of malignancies. It is beyond the scope of the article to discuss these studies in detail; 
however the NCI experience with cancer vaccination between 1995 and 2010 was reviewed in 2 separate publi- 
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Table 3. Phase I/II trials of co-stimulatory agents in GI malignancies in accrual.                                     
Disease Type Agent(s) Description Tumor Type Study Design/ Endpoints Dose and Schedule 
Pancreatic Ipilimumab +  
Gemcitabine 
Ipilimumab – CTLA-4  
inhibitor 
Recurrent/metastatic  
pancreatic carcinoma  
(NCT01473940) 
Non-randomized 
open-label phase I study 
 
Primary: Safety (MTD),  
toxicity 
 
Secondary: RR, irRC,  
TTP, PFS, OS 
Ipilimumab 
• IV ipilimumab q3 weeks for 4  
doses (induction) then q12  
weeks till progression  
(maintenance) 
 
Gemcitabine 
• IV gemcitabine qweekly  
(weeks 1 - 7, 9 - 11), then  
weekly 
FOLFIRINOX  
+ ipilimumab  
vs. 
FOLFIRINOX  
+ vaccine 
FOLFIRINOX –  
standard of care  
chemotherapy for  
pancreatic carcinoma 
 
Ipilimumab – CTLA-4  
inhibitor 
 
Vaccine-allogenic  
GM-CSF transfected  
pancreatic tumor  
vaccine 
 
Recurrent/metastatic  
pancreatic carcinoma  
(NCT01896869) 
Randomized open-label  
phase II study 
 
Primary: OS 
 
Secondary: PFS, irPFS 
Ipilimumab 
• IV ipilimumab 10 mg/kg q3  
weeks for 4 doses 
 
FOLFIRINOX q2 weeks: 
• IV oxaliplatin 85 mg/m2 D1 
• IV irinotecan 180 mg/m2 D1 
• IV leucovorin 400 mg/m2 D1 
• IV 5-FU 400 mg/m2 bolus then  
2400 mg/m2 over 46 hrs D1-2 
 
Allogenic GM-CSF transfected  
pancreatic tumor vaccine 
• 6 intra-dermal immunizations  
of 300 million immunotherapy  
cells days 1, 8, 15, 29, 43 and  
57 
• Additional 12 intra-dermal  
immunizations on days 1 and  
15 (of 4 week cycles) in  
patients with distant disease  
for up to 18 total doses 
Hepatocellular Nivolumab Nivolumab – PD-1  
inhibitor 
Advanced  
hepatocellular  
carcinoma  
(NCT01658878) 
Non-randomized 
open-label phase I study  
in 3 cohorts  
(non-infected,  
HCV-infected,  
HBV-infected) 
 
Primary: Safety/toxicity 
 
Secondary: ORR, DCR,  
PK 
IV nivolumab (0.3 mg/kg, 1  
mg/kg, 3 mg/kg, 10 mg/kg) q2  
weeks till progression 
Colorectal Ipilimumab  
+ Nivolumab 
Ipilimumab – CTLA-4  
inhibitor 
 
 
Nivolumab – PD-1  
inhibitor 
Recurrent/metastatic  
microsatellite high  
(MSI-H) colorectal  
carcinoma  
(NCT01928394,  
CheckMate 142) 
Non-randomized  
open-label phase I/II  
study 
 
Primary: OS 
 
Secondary: DFS 
Dose level -1 
• IV nivolumab 0.3 mg/kg + IV  
ipilimumab 1 mg/kg q3 weeks  
for 4 doses then IV nivolumab  
0.3 mg/kg q2 weeks till  
progression 
Dose level 1 
• IV nivolumab 1 mg/kg + IV  
ipilimumab 1 mg/kg q3 weeks  
for 4 doses then IV nivolumab  
1 mg/kg q2 weeks till  
progression 
 
Dose level 2a 
• IV nivolumab 1 mg/kg +IV  
ipilimumab 3 mg/kg q3 weeks  
for 4 doses then IV nivolumab  
1 mg/kg q2 weeks till  
progression 
Dose level 2b 
• IV nivolumab 3 mg/kg +  
IV ipilimumab 1 mg/kg  
q3 weeks for 4 doses then  
IV nivolumab 3 mg/kg  
q2 weeks till progression 
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 MK-3475 MK-3475 – PD-1  
inhibitor 
Recurrent/metastatic  
colorectal carcinoma  
(MSI and MSS) and  
non-colorectal MSI  
tumors(NCT01876511) 
Non-randomized 
open-label phase II study 
 
Primary: 20-week irPFS,  
20-week irOR 
 
Secondary: OS, RR, DCR 
MK-3475 
• MK-345 10 mg/kg q2  
weeks till progression 
MTD—maximal tolerated dose; RR—response rate; irOR—immune-related objective response; irRC—immune-related response criteria; TTP—time 
to progression; PFS—progression-free survival; irPFS—immune-related progression-free survival; OS—overall survival. 
 
cations and reported low response rates of 3% - 4% with only infrequent CRs in select malignancies [92] [93]. 
As TAA have been identified in esophageal (MAGE-A3/4 and NYESO-1), gastric (Her-2/neu), pancreatic 
(MUC1 and mesothelin), hepatocellular (AFP, GPC3, NY-ESO-1, SSX-2, MAGE-A and TERT) and colorectal 
(CEA) malignancies, cancer vaccination is an attractive strategy in GI malignancies. Given the lack of proven 
benefit in the phase III setting, no cancer vaccine is approved in the adjuvant, neo-adjuvant and/or advanced 
disease settings so far. The panoply of ongoing vaccine trials in GI malignancies is summarized in Table 4. 
Several early phase vaccine studies in CRC and esophagogastric cancers are in accrual. 
• Adjuvant CRC: phase I study of engineered alphavirus vaccine expressing CEA in stage III disease (NCT- 
01890213). 
• Advanced CRC: colorectal GVAX (in combination with Cy + DNA methyltransferase inhibitor SGI-110, 
NCT01309126); DC vaccination (NCT01348256); and polysaccharide beta 1,3/1,6 glucan(Imprime PGG) 
with cetuximab compared to cetuximab alone in KRAS WT patients at 1st progression (PRIMUS, NCT- 
01309126). 
• Adjuvant esophagogastric cancers following definitive surgery and combined modality therapy: NY-ESO-1 
expressing tumors (NCT01522820); cancer testis antigen expressing tumors (NCT01143545 and NCT- 
02054104). 
• Advanced gastric cancer: HER2 positive (AVX901-NCT01526473); and FOXM1/DEPDC1/KIF20A/ 
URLC10/VEGFR1 positive in patients withwith HLA-2402 haplotype (OTSGC-A24-NCT01227772). 
In advanced pancreatic cancer, several adjuvant vaccines have been developed including whole cell vaccines 
(Algenpantucel-L, GM-CSF vaccine); peptide and DNA vaccines [Ras, telomerase peptide, survivin, oncofetal 
peptides CEA/MUC1]; DC vaccines (utilizing CEA/MUC1 antigen pulsed DC cells) and heat-shock protein 
(HSP). Aside from Algenpantucel-L (HyperAcute®, NewLink Genetics Corporation) and GVAX, these ap- 
proaches have largely been unsuccessful and are reviewed elsewhere [94]. 
Algenpantucel-L is an allogeneic whole pancreatic cell vaccine engineered to express α-galactosyl (αGal) 
epitopes that elicit complement-mediated lysis and antibody-dependent cell-mediated toxicity. GVAX is a tumor 
cell vaccine created by harvesting allogenic cancer cells with subsequent transfection of the granulocyte macro- 
phage-colony stimulating factor (GM-CSF) gene. The algenpantucel-L phase II study involved 70 patients with 
resected pancreatic adenocarcinoma who received algenpantucel-L vaccination in addition to 5-FU/gemcitabine 
based chemoradiotherapy (investigational arm of RTOG-9704) post-operatively. Allowing for inherent biases in 
cross-trial comparisons, 12-month DFS and OS were improved with the addition of algenpantucel-L compared 
to 5-FU/gemcitabine chemoradiotherapy arm in RTOG-9704 [95] [96]. Algenpantucel-L is pending evaluation 
in a phase III study comparing 5-FU/gemcitabine chemoradiotherapy with or without algenpantucel-L immuni-
zation in resected high-risk pancreatic carcinoma (NCT01072981). 
Early studies of GVAX immunotherapy in renal cell cancer and melanoma produced middling results but the 
approach gained traction when an early study reported durable long-term responses in patients with advanced 
non-small cell lung cancer [97]. Both ipilimumab and GVAX have previously been evaluated in advanced pan- 
creatic adenocarcinoma with negative results previously [98] [99]. Recent work has shed light on the extensive 
immunosuppressive microenvironment encircling the primary tumor in pancreatic adenocarcinoma, and explains 
the poor results observed with conventional immunotherapeutic approaches in prior studies [100]. Paradoxically, 
given the limited access to host immune cells, pancreatic cells may actually be more sensitive to immune attack; 
and suggests that strategies that combine vaccination with immune checkpoint blockade may be more successful 
than unselected vaccination. Results of a recent phase Ib study combining GVAX vaccination and ipilimumab in 
advanced pancreatic adenocarcinoma patients in the 2nd line setting were promising [101]. This has prompted 
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Table 4. Trials of cancer vaccines in GI malignancies in accrual.                                                  
Disease Type Agent (Trade  name, Sponsors) Description Tumor Type Study Design/ Endpoints 
NY-ESO-1 
expressing 
tumors  
(esophageal,  
gastric, HCC,  
colorectal) 
DEC-205-NY- 
ESO-1 fusion  
protein vaccine 
mTOR inhibition with  
rapamycin for enhancing  
intranodal dendritic cell  
vaccine induced anti-tumor  
immunity in patients with  
NY-ESO-1 expressing solid  
tumors 
 
NY-ESO-1 expressing tumors  
following resection including  
esophageal, gastric, HCC and  
colorectal carcinomas  
(NCT01522820) 
Non-randomized phase I study of  
DEC-205-NY-ESO-1 fusion protein  
vaccine in combination with mTOR  
inhibitor sirolimus in NY-ESO-1  
expressing tumors following resection 
 
Primary: Safety 
 
Secondary: NY-ESO-1 specific cellular  
and humoral immunity 
Esophageal K562-GM tumor  
cell vaccine 
Allogeneic K562-GM tumor  
cell vaccine expressing cancer  
testis antigens 
Resected high-risk thoracic  
malignancies (including  
esophageal) expressing cancer  
testis antigens (NCT01143545) 
Non-randomized phase I/II study of  
K562-GM tumor cell vaccine in  
combination with metronomic oral  
cyclophosphamide and celecoxib 
 
Primary: Safety 
 
Secondary: Induction of immunity;  
reduction of T-regulatory cells in  
peripheral blood 
H1299 cell  
lysate/Iscomatrix 
vaccine 
Allogeneic H1299 cell  
lysate/Iscomatrix vaccine  
expressing cancer testis  
antigens 
Resected high-risk thoracic  
malignancies (including  
esophageal) expressing cancer  
testis antigens (NCT02054104) 
Randomized phase I/II study of H1299  
cell lysate/Iscomatrix vaccine with or  
without the combination with  
metronomic oral cyclophosphamide and  
celecoxib 
 
Primary: Immune response rates 
 
Secondary: Immune response rates 
Gastric AVX901 Recombinant Venezuelan  
equine encephalitis (VEE)  
alphavirus packaged in  
virus-like replicon particles  
(VRP) expressing HER2 
Metastatic HER2 positive cancers  
including gastric adenocarcinoma  
(NCT01227772) 
Non-randomized phase I study of  
AVX901 vaccine 
 
Primary: Safety 
 
Secondary: Induction of HER2 specific  
immunity 
OTSGC-A24 Allogeneic cell vaccine  
expressing tumor specific  
antigensand VEGFR1  
HLA-A24 epitopes 
Metastatic gastric adenocarcinoma  
(NCT01526473) 
Non-randomized phase I/IIa study of  
OTSGC-A24 vaccine 
 
Primary: Safety 
 
Secondary: Induction of T-effector  
specific immunity 
Pancreatic 
Cancer 
Algenpantucel-L 
(HyperAcute®, 
NewLink  
Genetics  
Corporation) 
Allogeneic whole pancreatic  
cells expressing α-galactosyl  
(αGal) epitopes that elicit  
complement-mediated lysis  
and antibody-dependent  
cell-mediated toxicity 
 
Resected high-risk pancreatic  
carcinoma 
(NCT01072981) 
Randomized open-label phase III trial of  
algenpantucel-L gemcitabine with or  
without 5-flurouracil (5FU)  
chemoradiation vs. gemcitabine with or  
without 5FU chemoradiation alone 
 
Primary: OS 
 
Secondary: DFS 
Borderline resectable or locally  
advanced unresectable pancreatic  
carcinoma (NCT01836432) 
Randomized open-label phase III trial of  
algenpantucel-L with FOLFIRINOX vs.  
FOLFIRINOX alone 
 
Primary: OS 
 
Secondary: PFS, immune response 
D. Davar, W. Sun 
 
 639 
Continued 
Pancreatic 
Cancer 
GVAX + 
CRS-207 
CRS-207-attenuated Listeria  
monocytogenes genetically  
engineered to elicit immune  
responses against  
tumor-associated mesothelin 
 
GVAX – tumor cell vaccine  
created by harvesting allogenic  
cancer cells with subsequent  
transfection of the granulocyte  
macrophage-colony  
stimulating factor (GM-CSF)  
gene. 
 
Cyclophosphamide (Cy) –  
low-dose metronomic  
cyclophosphamide 
Relapsed/refractory pancreatic  
carcinoma (ECLIPSE)  
(NCT02004262) 
Randomized open-label phase IIB trial  
of vs GVAX + CRS-207 vaccination.  
CRS-207 vaccination alone vs.  
chemotherapy 
 
Primary: OS 
 
Secondary: toxicity 
Colorectal  
carcinoma 
GVAX + Cy +  
SGI-110 
SGI-110 – DNA  
methyltransferase inhibitor 
 
GVAX – tumor cell vaccine  
created by harvesting allogenic  
cancer cells with subsequent  
transfection of the granulocyte  
macrophage-colony  
stimulating factor (GM-CSF)  
gene. 
 
Cyclophosphamide (Cy) –  
low-dose metronomic  
cyclophosphamide 
mCRC maintenance therapy 
(NCT01309126) 
Open-label phase I trial of SGI-110 in  
combination with GVAX/Cy as  
maintenance therapy 
 
Primary: Safety/toxicity 
 
Secondary: OS, PFS, TTP 
CEA(6D)-VRP 
(AVX701) 
Recombinant Venezuelan  
equine encephalitis (VEE)  
alphavirus packaged in  
virus-like replicon particles  
(VRP) expressing CEA (6D)  
(to enhance binding to  
HLA-A2, and enhanced  
recognition by TCR) 
Stage III colorectal carcinoma  
following completion of adjuvant  
5-FU based chemotherapy  
(NCT01890213) 
Open-label phase I trial of AVX701 
 
Primary: Safety/toxicity 
 
Secondary: None 
DC vaccine DC vaccination with  
autologous tumor antigen 
mCRC with hepatic metastasis  
following resection and standard  
adjuvant chemotherapy  
(NCT01348256) 
Open-label phase II trial of DC  
vaccination 
Imprime PGG  
and cetuximab or  
cetuximab alone 
Imprime PGG-polysaccharide  
beta 1.3/1.6 glucan derived  
from Saccharomyces cerevi 
siae cell wall 
Recurrent/metastatic KRAS WT  
CRC (PRIMUS) (NCT01309126) 
Randomized open-label phase III trial of 
cetuximab vs. cetuximab/Imprimg PGG 
 
Primary: OS 
 
Secondary: RR, PFS 
Hepatocellular 
Cancer 
COMBIG-DC Intra-tumoral DC vaccine Advanced HCC (NCT01974661) Open-label phase I trial of DC  
vaccination 
 
Primary: Safety/tolerability 
 
Secondary: RR, tumor marker (AFP) 
Cytokine-induced 
killer (CIK) cells 
Ex-vivo expanded T-cells  
which present a mixed T/NK  
phenotype and have  
MHC-unrestricted antitumor  
activity 
Hepatocellular carcinoma  
post-resection (NCT01749865) 
Randomized open-label phase III trial of  
standard care vs. CIK 
 
Primary: Time to recurrence 
 
Secondary: DFS 
PFS—progression-free survival; DFS—disease-free survival; OS—overall survival; TTP—time to progression; RR—response rate. 
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further investigation in the adjuvant setting with GVAX alone in combination with FOLFIRINOX, RT and 
low-dose cyclophosphamide (NCT01595321) and in advanced disease—GVAX/ipilimumab with FOLFIRINOX 
(NCT01896869), and GVAX with CRS-207 (ECLIPSE, NCT02004262). 
Vaccination is also an exciting option in HCC especially considering the presence of HCC-specific TAA 
(AFP, GPC3, NY-ESO-1, SSX-2, MAGE-A and TERT). Although the tolerogenic tumor micro-environment 
and HCC-specific tumor suppressive mechanisms are considerations underlying successful vaccination, several 
studies have demonstrated the validity of this approach. A Japanese study of 150 patients randomized following 
curative resection to either observation or vaccination with autologous lymphocytes activated in vitro by IL-2 
and anti-CD3 reported improved RFS and disease specific survival [102]. More recently, an autologous pulsed 
dendritic cell (DC) approach demonstrated clinical benefit in advanced disease [103]. Ongoing vaccine study 
strategies include intra-tumoral DC vaccination (NCT01974661), NY-ESO-1 vaccination in combination with 
sirolimus (NCT01522820) and adjuvant treatment following hepatectomy with cytokine-induced T-cells (NCT- 
01749865). 
3. Conclusions 
With the advent of efficacious cytotoxic options in GI malignancies, immunotherapeutic approaches were not 
pursued aggressively. However, the development and subsequent success of VEGF, EGFR and HER2 inhibition 
in several GI malignancies have rekindled interest in MoAbs targeting these axes in several settings. 
VEGF inhibition (bevacizumab, ziv-aflibercept and regorafenib) and EGFR inhibition (in KRAS/NRAS WT 
patients) have well defined roles in the management of metastatic CRC. In advanced KRAS/NRAS WT mCRC, 
both VEGF (bevacizumab) and EGFR (cetuximab/panitumumab) inhibition should be pursued. 
EGFR inhibition has no approved role in advanced HCC, esophagogastric, and pancreatic malignancies. 
Phase II studies of cetuximab-chemotherapy combinations in advanced cholangiocarcinoma appear promising 
but randomized phase III data are lacking. Aside from CRC, VEGF inhibition may have use in HCC though it 
appears unhelpful in pancreatic malignancies. The data in esophagogastric cancers are mixed. Although bevaci- 
zumab did not show the improvement in outcomes, ramucirumab demonstrated the survival benefit in a heavily 
pre-treated patient population with advanced gastric cancer (REGARD) [67], which suggests that alternative 
(and possibly more intense) VEGF pathway inhibition can improve outcomes, especially when combined with 
chemotherapy [68]. HER2 inhibition has a defined role in HER2+ esophagogastric malignancies. Continued 
HER2 inhibition post-progression and combined HER2 blockade are areas of ongoing interest. 
MSI-H CRC represents a distinct CRC subtype characterized by TAA expression that elicit a strong local 
(CD8+ T-cell infiltrates and peritumoral lymphoid nodules) host immune response [104] [105]. Immune check- 
points (PD-1 and CTLA-4) inhibitors may circumvent immune evasion that contributes to distant spread and the 
results of NCT01876511 (PD-1 in MSI-H CRC) and CheckMate 142/NCT01928394 (PD-1/CTLA-4 combina- 
tion in MSI-H CRC) are eagerly awaited. These observations also provide a strong mechanistic rationale for us- 
ing a peri-operative neoadjuvant approach in stage II/III MSI-H CRC. 
Although many GI malignancies have defined TAA, prior vaccine trials were largely negative. Current vac- 
cine studies are utilizing novel delivery systems [CEA expressing virus-like replicon particles (VRP)]; immu- 
nomodulatory strategies (low-dose metronomic cyclophosphamide); and are focusing on more immunogenic 
subtypes of GI malignancies (MSI-H CRC). 
Recent trials have validated diverse immunotherapeutic approaches in GI malignancies beyond MoAbs inhi- 
biting EGFR/VEGF. Existing MoAbs are being exploited in alternative settings and novel vaccine strategies are 
being developed. Immunotherapy is poised at the forefront of adjuvant, neoadjuvant and advanced approaches 
for the treatment and eradication of GI malignancies. 
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